Binding inhibition by monoclonal antibodies of ovine placental lactogen to growth hormone receptors in human liver.
In the radioreceptor assay for growth hormone (RRA-GH) using [125I]iodo-hGH, hGH and human liver membrane particulate fractions as tracer, hormone standard and receptors, respectively, ovine placental lactogen (oPL) is capable of inhibiting the binding of [125I]iodo-hGH in a parallel manner with hGH and in equipotency. Similarly, in the RRA-GH by employing [125I]iodo-oPL, oPL and human liver membrane particulate fractions as tracer, hormone standard and receptors, respectively, hGH is also equipotent as oPL in inhibiting the binding of [125I]iodo-oPL in a parallel fashion. The addition of monoclonal antibodies against oPL in the assay was effective in inhibiting the binding of [125I] iodo-oPL to human liver, but could not, however, inhibit the binding of [125I]iodo-hGH to human liver. Furthermore, the addition of the monoclonal antibodies in the RRA-GH did not affect the parallelism of the oPL standard but lowered the total binding of oPL. Our studies indicate that the structure of the binding sequence in oPL which binds to the GH receptor of human liver is not identical to the equivalent sequence of hGH and that the monoclonal antibodies compete with GH receptors in human liver for the binding of oPL.
D000818:Animals; D000911:Antibodies, Monoclonal; D002462:Cell Membrane / Q000378:metabolism; D013006:Growth Hormone / Q000031:analogs & derivatives / Q000378:metabolism; D006801:Humans; D007158:Immunologic Techniques; D008099:Liver / Q000378:metabolism*; D010928:Placental Lactogen / Q000276:immunology / Q000378:metabolism*; D011869:Radioligand Assay; D011956:Receptors, Cell Surface / Q000378:metabolism*; D011986:Receptors, Somatotropin; D012756:Sheep
D000911:Antibodies, Monoclonal; D011956:Receptors, Cell Surface; D011986:Receptors, Somatotropin; C035648:somatotropin, iodinated; D013006:Growth Hormone; D010928:Placental Lactogen